Targeted radiotherapy using Auger electron emitters
Targeted radiotherapy using Auger electron emitters
复制标题
DOI：
10.1088/0031-9155/41/10/009
复制
发表时间：
1996-10-01
影响因子：
3.5
通讯作者：
Wheldon, TE
中科院分区：
文献类型：
--
作者：
ODonoghue, JA;Wheldon, TE
俄歇发射的放射性核素由于其高水平的细胞毒性和短程生物学效应而具有用于癌症治疗的潜力。生物效应严重依赖于俄歇发射体的亚细胞（和亚核）定位。数学模型研究表明，使用半衰期短的放射性核素（如I-123）比使用半衰期长的放射性核素（如I-125）在理论上更有优势。此外，放射性核素摄取的异质性预计将严重限制靶向俄歇疗法的最终治疗效果。可能的靶向方法包括使用DNA前体的类似物如碘-脱氧尿苷和结合DNA的分子如类固醇激素或生长因子。更长期的可能性是使用诸如寡核苷酸的分子，其可以在DNA序列水平上进行区分。靶向俄歇治疗的最佳临床作用似乎是作为治疗选定恶性疾病的多模态治疗策略的一个组成部分。
Auger-emitting radionuclides have potential for the therapy of cancer due to their high level of cytotoxicity and short-range biological effectiveness. Biological effects are critically dependent on the sub-cellular (and sub-nuclear) localization of Auger emitters. Mathematical modelling studies suggest that there are theoretical advantages in the use of radionuclides with short half-lives (such as I-123) in preference to those (such as I-125) with long half-lives. In addition, heterogeneity of radionuclide uptake is predicted to be a serious limitation on the ultimate therapeutic effect of targeted Auger therapy. Possible methods of targeting include the use of analogues of DNA precursors such as iodo-deoxyuridine and molecules which bind DNA such as steroid hormones or growth factors. A longer term possibility may be the use of molecules such as oligonucleotides which can discriminate at the level of DNA sequence. It seems likely that the optimal clinical role of targeted Auger therapy will be as one component of a multi-modality therapeutic strategy for the treatment of selected malignant diseases.